MedTrace Logo

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06574568 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-02-05

No results posted yet for this study

Summary

This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.

Conditions

Interventions

DRUG

YKST02

BCMA-CD3 bispecific antibody

Sponsors & Collaborators

  • Excyte Biopharma Ltd

    lead INDUSTRY

Principal Investigators

  • Wenming Chen, MD · Beijing Chao Yang Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-14
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06574568 on ClinicalTrials.gov